TRIB Earnings

TRIB reported its FY2024Q3 earnings on 2024-11-15, showcasing a revenue of 15.15M against an estimate of 16.50M, resulting in a -8.17% surprise. The EPS was -0.43, surpassing the expected -0.54 by 20.37% . The stock experienced a -7.43% price change on the earnings day and a -12.16% change over the next five days, reflecting market reactions to the results.

Following TRIB's FY2024Q3 earnings announcement on 2024-11-15, the stock price moved by -7.43% on the day of the release. Over the subsequent five days, it saw a -12.16% change. Historically, TRIB's stock price tends to shift by an average of +11.69% in the 10 days leading up to earnings and -5.62% in the 10 days following, providing insight into potential market.

For 2024/Q4, analysts estimate TRIB’s annual revenue to reach 16.50M, while the EPS is projected at -0.30. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between TRIB's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TRIB's stock price typically moves by +11.69% in the 10 days before its earnings and -5.62% in the 10 days after. For the upcoming 2024/Q4 earnings, analysts expect an EPS of -0.30 and revenue of 16.50M.

The earnings call reveals mixed signals. Financial performance shows improvement in losses and revenue growth in key areas, but there are ongoing financial challenges, competitive pressures in the CGM market, and operational risks due to restructuring. The lack of a clear shareholder return plan and unclear management responses in the Q&A add uncertainty. Despite positive revenue growth in TrinScreen HIV and cost reduction efforts, the net loss and financial risks limit optimism, resulting in a neutral stock price prediction.